User login
Dr. James Ingle discusses findings that adjuvant therapy with aromatase inhibitors cuts the risk of recurrent breast cancer, compared with tamoxifen. Kerri Wachter of Elsevier Global Medical News (EGMN) reports from the annual San Antonio Breast Cancer Symposium.
Dr. James Ingle discusses findings that adjuvant therapy with aromatase inhibitors cuts the risk of recurrent breast cancer, compared with tamoxifen. Kerri Wachter of Elsevier Global Medical News (EGMN) reports from the annual San Antonio Breast Cancer Symposium.
Dr. James Ingle discusses findings that adjuvant therapy with aromatase inhibitors cuts the risk of recurrent breast cancer, compared with tamoxifen. Kerri Wachter of Elsevier Global Medical News (EGMN) reports from the annual San Antonio Breast Cancer Symposium.